)
Lupin Pharmaceuticals Inc., US subsidiary of Lupin Ltd, has signed a strategic co-promotion agreement with US-based Onset Dermatologics, LLC that grants Lupin exclusive rights to promote Onset’s Locoid Lotion (hydrocortisone butyrate 0.1%) to pediatricians in the US.
Locoid Lotion is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients of 3 months of age and older. Atopic Dermatitis (AD) is one of the most common skin disorders in young children and has a prevalence of 10 to 20% in the first decade of life. It is a chronic illness that requires a multifaceted treatment strategy in the setting of limited therapeutic options, said a company statement.
AD, more commonly called eczema, now affects 10 to 20% of children in the United States and direct health-care costs exceed $3 billion, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Locoid Lotion currently participates in a market that includes 17% of school-age children in the US between the ages of 5 – 7 years which is about 9.2 million children.
Lupin's product portfolio for the US pediatrics segment consists of Suprax and Alinia for Oral Suspension.
